B Braun inks deal to buy NxStage ’ s bloodlines biz
B. Braun said today it inked a deal to acquire the NxStage Medical‘s (NSDQ:NXTM) bloodlines business, which operates under the Medisystems moniker. Bethlehem, Penn.-based B. Braun did not release any details of the acquisition, and has not revealed how it plans to integrate the business into its existing product lines. “We are pleased to add the Streamline bloodline to our dialysis product portfolio. Although we have been selling Streamline for many years, this acquisition will allow us to more broadly promote Streamline’s benefits as part of our transformative system of products, which includes...
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions B. Braun NxStage Medical Inc. Source Type: news

Top symptoms of aluminum poisoning and toxicity
(Natural News) Exposure to high levels of aluminum may lead to potentially harmful toxicity. Old age and reduced kidney function are two most common risk factors associated with aluminum poisoning. According to an article published in Medscape.com, aluminum toxicity is commonly found in patients with renal impairment. Long-term hemodialysis is also linked to increased odds of aluminum... (Source: NaturalNews.com)
Source: NaturalNews.com - July 14, 2018 Category: Consumer Health News Source Type: news

BD closes TVA Medical buy
Becton Dickinson (NYSE:BDX) wasted no time in closing the cash buyout of  TVA Medical, which just a few weeks ago landed FDA clearance for its EverlinQ EndoAVF hemodialysis device, for an undisclosed amount. Austin, Texas-based TVA won de novo clearance June 22 for the EverlinQ EndoAVF device, which uses a pair of magnetic catheters and radiofrequency energy to create an arteriovenous fistula for hemodialysis access without open surgery. BD said today that it plans to change the system’s name to WavelinQ EndoAVF as it integrates TVA into its peripheral intervention business. “The FDA’s...
Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Dialysis Mergers & Acquisitions bectondickinson TVA Medical Source Type: news

$65B global giant Becton Dickinson buys Austin company making life easier for those with kidney disease
Becton Dickinson and Co., or BD, has purchased Austin medical-device company TVA Medical Inc. Financial terms were not disclosed but the deal hands control of a small company in the Texas capital's medical-technology world to a global player with annual revenue in the 11 figures. It's an exit sure to be watched by other local medical-device companies such as Ortho Kinematics Inc. and Alaf air Biosciences Inc. TVA Medical, founded in 2009, makes it easier for doctors to create hemodialysis access,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 9, 2018 Category: Pharmaceuticals Authors: Will Anderson Source Type: news

Fresenius Medical Care offers $585m in notes
Fresenius Medical Care (NYSE:FMS; ETR:FRE) this week successfully placed notes with an aggregate principal amount of €500 million ($584.9 million). The notes will mature in 7 years and have an annual coupon of 1.5%, the company noted. Fresenius reported that the issue price is 99.704% and the resulting yield amounts to 1.545%. “The transaction was very well received by investors and substantially oversubscribed. The proceeds will be used for general corporate purposes, including the refinancing of upcoming maturities,” Fresenius said in a press release. Last week, the medtech giant inked a $150 m...
Source: Mass Device - July 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Dialysis Funding Roundup Wall Street Beat Fresenius Source Type: news

FDA Permits Marketing of Devices to Create Arteriovenous Fistula
TUESDAY, July 3, 2018 -- The U.S. Food and Drug Administration has permitted marketing of two catheter-based devices designed to create an arteriovenous (AV) fistula in patients with chronic kidney disease in need of hemodialysis. The devices are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 3, 2018 Category: Pharmaceuticals Source Type: news

Few Hemodialysis Patients on Medicare Enroll in Hospice
WEDNESDAY, June 27, 2018 -- Among Medicare beneficiaries on hemodialysis, few patients are enrolled in hospice at the end of life, regardless of the spending trajectory during the last year of life, according to a study published in the June issue... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 27, 2018 Category: Pharmaceuticals Source Type: news

Ellipsys & #039; FDA Nod Is a Major Turning Point for Hemodialysis
A new catheter-based technology could provide a non-surgical option for arteriovenous (AV) fistula creation. FDA recently gave de novo clearance to Avenu Medical’s Ellipsys Vascular Access System. The San Juan Capistrano, CA-based company’s device challenges the surgical option to create an AV fistula, which has been the gold standard for about 50 years. “This is what we call a disruptive technology for sure,” Ed Chang, Co-Founder, Director and VP Marketing for Avenu, told MD+DI. “We liken this to lap chole. Prior to lap chole it was always done surgically. That was the gold standard until lap...
Source: MDDI - June 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

FDA grants de novo clearance to Avenu Medical for Ellipsys vascular access system
Vascular access system maker Avenu Medical said today it won FDA de novo clearance for its Ellipsys vascular access system designed for use with end-stage renal disease patients who require hemodialysis. The San Juan Capistrano, Calif.-based company touted that its Ellipsys EndoAVF technology acts as an alternative to traditional AV fistula creation. The system, which can be used under local or regional anesthesia, uses an ultrasound-guided catheter that delivers a small amount of thermal energy to fuse a permanent anastomosis between the vein and artery to create an AVF. “Using the Ellipsys vascular access...
Source: Mass Device - June 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Regulatory/Compliance Vascular Avenu Medical Source Type: news

A Tool for Incremental Hemodialysis Prescription A Tool for Incremental Hemodialysis Prescription
A new, easy to use spreadsheet may be a helpful tool for the prescription of incremental hemodialysis.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

FDA approves catheter-based systems that offer vascular access for hemodialysis
The FDA has approved marketing two catheter-based devices to connect to veins and arteries in patients with chronic kidney disease who need hemodialysis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 25, 2018 Category: Consumer Health News Source Type: news

Austin medical device company gets FDA approval for kidney-disease treatment
TVA Medical Inc. has received federal authorization to sell a medical device that could change how people suffering from serious kidney disease receive treatment. The Austin-based company announced June 22 that it has received "de novo" authorization from the U.S. Food and Drug Administration for its EverlinQ EndoAVF System, a minimally invasive piece of equipment that can give doctors hemodialysis access to a patient using magnetic catheters and radiofrequ ency energy. Once a person's kidneys can… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 25, 2018 Category: American Health Authors: Will Anderson Source Type: news

FDA OKs Two Devices for Endovascular AV Fistula Creation FDA OKs Two Devices for Endovascular AV Fistula Creation
The Ellipsys Vascular Access System and the everlinQ endoAVF System create arteriovenous fistulas percutaneously in patients with chronic kidney disease who need hemodialysis access.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 22, 2018 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news

News Release: #FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients https://go.usa.gov/xUqu9   #medicaldevice
News Release: #FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients https://go.usa.gov/xUqu9  #medicaldevice (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - June 22, 2018 Category: Medical Devices Authors: ( at FDADeviceInfo) Source Type: news

FDA grants de novo clearance to hemodialysis catheters from Avenu Medical, TVA Medical
The FDA today granted de novo clearance to a pair of companies that make catheters designed for hemodialysis, Avenu Medical and TVA Medical. The federal safety watchdog said the catheters are designed to create an arteriovenous fistula connecting veins and arteries for a less-invasive way to access the vascular system. Avenu’s device is called Ellipsys; TVA Medical makes the EverlinQ EndoAVF system. “Dialysis is a necessary and life-saving procedure for thousands of individuals. With today’s action, there will be additional, less-invasive vascular access options for patients who will require hemodial...
Source: Mass Device - June 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Catheters Dialysis Food & Drug Administration (FDA) Regulatory/Compliance Avenu Medical TVA Medical Source Type: news

FDA permits marketing of first catheter-based systems used to create vascular access for hemodialysis patients
(Source: Food and Drug Administration)
Source: Food and Drug Administration - June 22, 2018 Category: American Health Source Type: news

Hemoglobin Concentration and Stroke Risk in Hemodialysis Hemoglobin Concentration and Stroke Risk in Hemodialysis
Might low hemoglobin concentrations contribute to the risk for hemorrhagic or ischemic stroke among hemodialysis patients?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Fresenius Medical Care, Humacyte ink $150m strategic partnership deal
Fresenius Medical Care (NYSE:FMS; ETR:FRE) said today it inked a $150 million strategic partnership deal with Humacyte through which Fresenius will gain exclusive rights to commercialize Humacyte’s Humacyl bioengineered blood vessel technology. Research Triangle Park, N.C.-based Humacyte is exploring the use of its Humacyl human acellular vessel as a conduit for hemodialysis in patients with end-stage renal disease who cannot have fistula placement. Fresenius Medical will now be responsible for the marketing, sales and distribution of Humacyl following appropriate regulatory approval, the companies said. Fr...
Source: Mass Device - June 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Vascular Fresenius Humacyte Source Type: news

FDA Approves Mircera for Anemia Associated with Chronic Kidney Disease in Pediatric Patients on Dialysis
On June 7, 2018, the Food and Drug Administration approved methoxy polyethylene glycol-epoetin beta (Mircera, Vifor Pharma Inc.) for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 7, 2018 Category: Drugs & Pharmacology Source Type: news

Baxter touts Theranova HDx dialysis tech study data
Baxter (NYSE:BAX) today released new data from studies exploring expanded hemodialysis with its Theranova dialyzer, touting the device’s ability to clear large middle molecules at a higher rate than standard hemodialysis and equal or faster removal rates compared to high-volume hemodiafiltration. Results from a number of studies and poster presentations on the Theranova dialyzer were presented at the 55th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this month, Baxter said. The Deerfield, Ill.-based company’s Theranova dialyzer is designed to exte...
Source: Mass Device - May 31, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Dialysis Baxter Source Type: news

Pursuit Vascular wins expanded indication for antimicrobial device
ClearGuard HD antimicrobial caps [Image courtesy of Pursuit Vascular]Pursuit Vascular (Maple Grove, Minn.) today announced that it has won FDA clearance for a broader indication of its ClearGuard HD antimicrobial caps. The new indication for the caps — used as an antimicrobial device for catheter-based dialysis patients — includes reduction in the incidence of central-line associated bloodstream infection in hemodialysis patients with central venous catheters. Get the full story on our sister site Medical Design & Outsourcing.  The post Pursuit Vascular wins expanded indication for antimicrobial d...
Source: Mass Device - May 30, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: 510(k) Business/Financial News Catheters Dialysis Food & Drug Administration (FDA) News Well Regulatory/Compliance infections Pursuit Vascular Source Type: news

FDA Broadens ClearGuard(R) HD Antimicrobial Barrier Cap Indications
ClearGuard HD Caps Have Been Shown to Reduce Central Line-Associated Bloodstream Infections in Hemodialysis Patients MAPLE GROVE, Minn., May 30, 2018 -- (Healthcare Sales & Marketing Network) -- Pursuit Vascular, Inc., manufacturer of ClearGuard HD Ant... Devices, FDA Pursuit Vascular, ClearGuard, Antimicrobial Barrier, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2018 Category: Pharmaceuticals Source Type: news

TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten(R) for the Treatment of Intradialytic Hypotension
Phase II clinical trials in patients undergoing hemodialysis to be initiated in Q4, 2018 NEWARK, Delaware, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- TrioxBio Inc., a clinical-stage biopharmaceutical company specializing in the developme... Biopharmaceuticals, FDA TrioxBio, Raviten, ethylisothiouronium, Intradialytic Hypotension, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

Moral Distress for Docs Providing Emergency - Only Hemodialysis
Docs describe burnout and emotional exhaustion; moral distress at seeing suffering and injustice (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - May 22, 2018 Category: Psychiatry Tags: Endocrinology, Internal Medicine, Emergency Medicine, Nephrology, Nursing, Psychiatry, Journal, Source Type: news

A holistic approach to factors affecting depression in haemodialysis patients - Gerogianni G, Kouzoupis A, Grapsa E.
Depression in dialysis populations is affected by co-morbid diseases, such as cardiovascular disease, diabetes, and immune dysfunction, and it also includes high suicide risk and frequent hospitalizations. Depressive disorders have a close association with... (Source: SafetyLit)
Source: SafetyLit - May 22, 2018 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Moral Distress for Docs Providing Emergency-Only Hemodialysis
TUESDAY, May 22, 2018 -- Clinicians who provide emergency-only hemodialysis (EOHD) to undocumented immigrants experience moral distress and professional burnout, according to a study published online May 22 in the Annals of Internal Medicine. Noting... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 22, 2018 Category: Pharmaceuticals Source Type: news

Physicians report feeling moral distress over hospital policies that force inadequate care
(American College of Physicians) Clinicians in safety-net hospitals describe feeling moral distress and being driven toward professional burnout because of policies that prevent them from performing hemodialysis to undocumented immigrants, except in the case of an emergency. Being forced to provide inferior care due to the patient's immigration status was a significant burden to the clinicians who reported feeling a sense of admiration for these patients and a desire to advocate on their behalf. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 21, 2018 Category: International Medicine & Public Health Source Type: news

Mortality in Patients on Hemodiafiltration vs Hemodialysis Mortality in Patients on Hemodiafiltration vs Hemodialysis
Might hemodiafiltration patients realize better outcomes than those receiving hemodialysis?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Making Dialysis Safer for Patients: Tools to Prevent Infections in Hemodialysis
May 18, 2018 2:00-3:15pm ET. (Source: HSR Information Central)
Source: HSR Information Central - May 8, 2018 Category: International Medicine & Public Health Source Type: news

Access to hemodialysis technology: From Toronto to Addis Ababa
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - May 2, 2018 Category: Hospital Management Tags: Hospital News Source Type: news

Opioids Tied to Adverse Outcomes in Hemodialysis Patients
THURSDAY, April 19, 2018 -- For patients on hemodialysis, opioids are associated with adverse outcomes, according to a study published online April 19 in the Clinical Journal of the American Society of Nephrology. Julie H. Ishida, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2018 Category: Pharmaceuticals Source Type: news

Antifreeze poisoning : the case of a  patient with repeated ethylene glycol poisoning - Prinz J, Böll B, von Bergwelt M, Burst V, Becker JU, Carvalho-Fiel D, Shimabukuro-Vornhagen A, Kochanek M.
Ethylene glycol poisoning of incidental or suicidal intention can cause life-threatening metabolic acidosis, diverse secondary damage, and even lead to death. Beside hemodialysis effective therapy consists of the administration of fomepizole and ethanol. W... (Source: SafetyLit)
Source: SafetyLit - April 16, 2018 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

CVS is diving into the dialysis market
Drug store operator CVS Health (NYSE:CVS) said today it plans to expand into the dialysis market, launching a program focused on early identification of kidney disease and unveiling plans to develop a new home hemodialysis system. CVS said it will approach its entry into the dialysis market in stages, focusing on early disease identification and education, followed by the development of a home dialysis program for both hemodialysis and peritoneal dialysis. As part of its program, the company said it will launch a pivotal trial of a new home hemodialysis system in support of planned FDA submission, though it has not ye...
Source: Mass Device - April 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development CVS Health Source Type: news

Notes from the Field: False-Negative Hepatitis B Surface Antigen Test Results in a Hemodialysis Patient — Nebraska, 2017
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - March 15, 2018 Category: American Health Source Type: news

Genetic Variants Linked to Earlier Kidney Failure in African Americans
African Americans with APOL1 gene experience faster rate of decline in kidney function and begin hemodialysis at a younger age versus those without the gene. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Humacyte closes $75m Series C round
Humacyte said today that it raised $75 million in a Series C preferred stock financing, led by a group of existing private investors and new investors. The Research Triangle Park, N.C.-based company expects to use its newly-acquired funds to support an on-going Phase III pivotal study evaluating its human acellular vessel, Humacyl, as a conduit for hemodialysis in patients with end-stage renal disease who cannot have fistula placement. Humacyte finished enrolling participants in the 350-patient trial last September and anticipates 12-month post-implantation data to be available in the third quarter of 2018. The company als...
Source: Mass Device - March 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Funding Roundup Vascular Humacyte Inc. Source Type: news

Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma Source Type: news

Wearable Artificial Kidney Could be Game Changer
Most innovations medicine occur by asking one simple question. Is there a better way? Physicians at the Kidney Research Institute of the University of Washington have asked that question about hemodialysis treatments – lengthy procedures that filter a patient’s blood when the kidneys no longer function properly. The institute is developing a wearable artificial kidney that could completely change the paradigm for some of these patients with impaired kidney function. Earlier this week, at MD&M West, Jonathan Himmelfarb, MD, who servers as director of the Kidney Research Institute, spoke about the develo...
Source: MDDI - February 8, 2018 Category: Medical Devices Authors: Omar Ford Tags: Medical Device Business Source Type: news

WHO calls for sustainable solution to health sector power shortages in Gaza
8 February, 2018, Gaza Strip – Gaza’s health sector was on the verge of collapse due to dwindling fuel supplies until the United Arab Emirates stepped in this week with a US$2 million grant to sustain hospital backup generators for critical health services. The donation will provide enough fuel to keep facilities running for several months.  “The UAE’s timely support will save lives, but a more sustainable solution is required to address the chronic fuel and power shortages in Gaza that leave health facilities consistently on the verge of closure,” says Dr. Gerald Rockenschaub, Head of W...
Source: WHO EMRO News - February 8, 2018 Category: Middle East Health Source Type: news

TVA Medical touts meta-analysis of everlinQ endoAVF treatments
TVA Medical today released data from a meta-analysis study of its everlinQ endovascular arteriovenous fistula system designed for hemodialysis access, touting a high procedure success rate and a high rate of fistula maturation. Results from the 236-patient trial were presented at the Leipzig Interventional Course 2018, the Austin, Texas-based company said. Data in the meta-analysis came from four clinical studies and 79 commercial cases, and indicated a 96.8% and 97.8% procedure success rate in clinical studies and real-world cases, respectively, as well as an acceptable safety profile. The results also indicated 88% fistu...
Source: Mass Device - February 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Vascular TVA Medical Source Type: news

Comprehensive up-to-date review of toxic alcohol poisoning
3.5 out of 5 stars Toxic Alcohols. Kraut JA, Mullins ME. N Engl J Med 2018 Jan 18;378:270-280. Reference This is a good general review and update of clinical issues regarding the major toxic alcohols: methanol, ethylene glycol, isopropanol, diethylene glycol, and propylene glycol. The article is chockablock with information, and would I think be somewhat difficult to follow if one was not already familiar with these agents. For those wishing to learn the subject de novo, a good introductory book chapter in a toxicology or emergency medicine text would be better. But this is a very good refresher for those already...
Source: The Poison Review - January 30, 2018 Category: Toxicology Authors: Leon Gussow Tags: Medical diethylene glycol isopropanol methanol propylene glycol Review toxic alcohol Source Type: news

Serious fall injury history and adverse health outcomes after initiating hemodialysis among older U.S. adults - Bowling CB, Hall R, Khakharia A, Franch HA, Plantinga LC.
BACKGROUND: Although older adults with pre-dialysis chronic kidney disease (CKD) are at higher risk for falls, the prognostic significance of a serious fall injury prior to dialysis initiation has not been well described in the end-stage renal disease popu... (Source: SafetyLit)
Source: SafetyLit - January 22, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Laminate Medical launches study of VasQ hemodialysis fistula device
Laminate Medical Technologies said today it launched a pivotal, FDA-cleared trial of its VasQ implanted blood vessel device designed for patients requiring arteriovenous fistulas as vascular access for hemodialysis. The Israel-based company’s VasQ device is designed to aid kidney failure patients in need of dialysis by providing external support to reduce fistula failure. The device regulates flow by constraining and shaping the fistula and reinforces and shields the perianastomotic vein against high pressure, wall tension and flow levels, the company said. The first procedures in the trial were recently perform...
Source: Mass Device - January 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Vascular Laminate Medical Technologies Source Type: news

Baxter subsidiary sues B. Braun over blood filtration system
Baxter (NYSE:BAX) and its subsidiary Gambro filed a patent infringement lawsuit against B. Braun last week, claiming that the German medical device maker’s Omni blood purification system infringes on seven of the patents covering Baxter’s Prismaflex system. The devices are used to treat patients who have acute kidney injuries and need help filtering out the waste products that accumulate in the blood. Both the Omni system and the Prismaflex system deliver continuous renal replacement therapy – a form of hemodialysis where the patient’s blood is removed and processed through a hemofilter. B...
Source: Mass Device - January 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Legal News Wall Street Beat B. Braun Baxter Gambro Source Type: news

Bluegrass Vascular launches pivotal study for Surfacer vascular access catheter
Bluegrass Vascular Technologies said it enrolled the first patients in a pivotal trial of its Surfacer “inside-out” vascular access catheter. The Surfacer device is designed to provide access to the jugular vein to restore central venous access in hemodialysis patients with blocked neck veins; it won CE Mark approval in the European Union in August 2016; Bluegrass later inked an EU distribution deal with Merit Medical (NSDQ:MMSI) that included an equity stake. Surfacer is designed to be threaded through the femoral vein up to and into blockages in the jugular, which acts as a stabi...
Source: Mass Device - January 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Vascular Bluegrass Vascular Technologies Source Type: news

Autogenous Conduits for Leg Bypass Surgery Used Less Often in Female Dialysis Patients Autogenous Conduits for Leg Bypass Surgery Used Less Often in Female Dialysis Patients
Autogenous conduits improve patency in hemodialysis patients undergoing lower-extremity bypass surgery, but are used less often in women than in men, new research shows.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 8, 2018 Category: Surgery Tags: General Surgery News Source Type: news

These lab-grown blood vessel replacements could benefit dialysis patients
[Image from University of Minnesota]University of Minnesota researchers have developed a blood vessel replacement made of biological materials in a lab. The lab-grown vessels have no living cells at implantation and could be used as a graft for kidney dialysis patients. The lab-engineered blood vessel replacement is the first nonsynthetic, decellularized graft that is repopulated with cells using the recipient’s cells when implanted. The grafts could also be used as coronary and peripheral bypass blood vessel and tubular heart valves. Approximately 480,000 people are on dialysis in the U.S., according to the National...
Source: Mass Device - January 3, 2018 Category: Medical Devices Authors: Danielle Kirsh Tags: Implants Regenerative Medicine Research & Development kidney dialysis MedTech University of Minnesota Source Type: news

Emergency-Only Dialysis Ups Deaths in Undocumented Immigrants Emergency-Only Dialysis Ups Deaths in Undocumented Immigrants
Undocumented immigrants with end-stage renal disease who accessed hemodialysis on a emergency-only basis were more likely to die and to spend more time hospitalized, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 19, 2017 Category: Consumer Health News Tags: Nephrology News Source Type: news

Uric Acid, Protein and Mortality in Hemodialysis Patients Uric Acid, Protein and Mortality in Hemodialysis Patients
What do we currently know about the association between uric acid concentrations and mortality in hemodialysis patients -- and how does protein intake fit into the equation?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 19, 2017 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Body Weight Changes and Mortality in Hemodialysis Patients Body Weight Changes and Mortality in Hemodialysis Patients
A new study examines the association of post-dialysis weight changes with all-cause mortality in hemodialysis patients.Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2017 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news